249 related articles for article (PubMed ID: 14973080)
1. Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Robey RW; Steadman K; Polgar O; Morisaki K; Blayney M; Mistry P; Bates SE
Cancer Res; 2004 Feb; 64(4):1242-6. PubMed ID: 14973080
[TBL] [Abstract][Full Text] [Related]
2. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.
Robey RW; Steadman K; Polgar O; Bates SE
Cancer Biol Ther; 2005 Feb; 4(2):187-94. PubMed ID: 15684613
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
6. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput cell-based assay for inhibitors of ABCG2 activity.
Henrich CJ; Bokesch HR; Dean M; Bates SE; Robey RW; Goncharova EI; Wilson JA; McMahon JB
J Biomol Screen; 2006 Mar; 11(2):176-83. PubMed ID: 16490770
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
9. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
Robey RW; Shukla S; Steadman K; Obrzut T; Finley EM; Ambudkar SV; Bates SE
Mol Cancer Ther; 2007 Jun; 6(6):1877-85. PubMed ID: 17575116
[TBL] [Abstract][Full Text] [Related]
11. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
12. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
15. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Katayama R; Koike S; Sato S; Sugimoto Y; Tsuruo T; Fujita N
Cancer Sci; 2009 Nov; 100(11):2060-8. PubMed ID: 19673889
[TBL] [Abstract][Full Text] [Related]
16. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
Ozvegy-Laczka C; Várady G; Köblös G; Ujhelly O; Cervenak J; Schuetz JD; Sorrentino BP; Koomen GJ; Váradi A; Német K; Sarkadi B
J Biol Chem; 2005 Feb; 280(6):4219-27. PubMed ID: 15557326
[TBL] [Abstract][Full Text] [Related]
17. A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo.
Kokubo S; Ohnuma S; Murakami M; Kikuchi H; Funayama S; Suzuki H; Kajiwara T; Yamamura A; Karasawa H; Sugisawa N; Ohsawa K; Kano K; Aoki J; Doi T; Naitoh T; Ambudkar SV; Unno M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830383
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
19. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Morfouace M; Cheepala S; Jackson S; Fukuda Y; Patel YT; Fatima S; Kawauchi D; Shelat AA; Stewart CF; Sorrentino BP; Schuetz JD; Roussel MF
Cancer Res; 2015 Sep; 75(18):3879-89. PubMed ID: 26199091
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
